Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Bibliographic Details
Main Authors: D Papaioannou, R Rafia, J Rathbone, M Stevenson, H Buckley Woods, J Stevens
Format: Article
Language:English
Published: NIHR Journals Library 2012-10-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta16370

Internet

https://doi.org/10.3310/hta16370

Similar Items